论文部分内容阅读
目的:研究和探讨FOLFIRI方案二线治疗晚期结直肠癌的效果,为日后临床治疗提供参考价值。方法:选择2009年12月到2013年12月来我院进行晚期结直肠癌治疗的患者,其中58例患者一线FOLFOX4化疗失败,改用FOLFIRI方案进行二线挽救治疗,观察和分析临床治疗效果。结果:58例患者出现呕吐、恶心38例,占65.52%;腹泻等胃肠道疾病21例,占36.21%;口腔炎16例,占27.59%;血小板数降低13例,占22.41%;脱发9例,占15.52%;贫血7例,占12.07%;肝肾功能衰竭5例,占8.62%。其中,晚期结直肠癌完全缓解8例,病情稳定14例,无效36例,临床治疗有效率为37.93%。结论:使用FOLFIRI方案对晚期结直肠癌进行二线化疗治疗,临床疗效可观,且临床不良反应可以得到控制,具有推广价值。
Objective: To study and explore the effect of second-line FOLFIRI in the treatment of advanced colorectal cancer and provide reference value for future clinical treatment. Methods: From December 2009 to December 2013, patients with advanced colorectal cancer who came to our hospital from December 2009 to December 2013 were enrolled. Among them, 58 patients underwent first-line FOLFOX4 chemotherapy failure and were treated with FOLFIRI for second-line salvage therapy. The clinical effects were observed and analyzed. Results: Fifty-eight patients had vomiting, nausea 38 cases, accounting for 65.52%; diarrhea and other gastrointestinal diseases 21 cases, accounting for 36.21%; stomatitis 16 cases, accounting for 27.59%; platelet count decreased 13 cases, accounting for 22.41%; hair loss 9 Cases, accounting for 15.52%; anemia in 7 cases, accounting for 12.07%; liver and kidney failure in 5 cases, accounting for 8.62%. Among them, the complete remission of advanced colorectal cancer in 8 cases, 14 cases of stable, ineffective in 36 cases, clinical treatment efficiency was 37.93%. Conclusion: FOLFIRI regimen for second-line chemotherapy in patients with advanced colorectal cancer, clinical efficacy is considerable, and clinical adverse reactions can be controlled, with the promotion of value.